Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2005

View Archived Issues

IoGen begins phase III trials

Duska acquires P2 receptor-based technology to treat glaucoma

Kalypsys and NovImmune form collaboration

Napo grants AsiaPharm license for crofelemer products in China

Good safety profile reported for new topical indomethacin in healthy subjects

First clinical data on the protective effects of FluBlOk against influenza

Update on the effects and safety of istradefylline in Parkinson's disease

Albumin therapy improves outcome after ischemic stroke

Pulsatile amoxicillin reported less effective than penicillin in strep throat

Novasite acquires PsyCheNomicS

New share issue to raise funds for alpha-HGA development at Tripep

BiDil recommended for heart failure in self-identified African Americans

Preclinical results for Senesco's Factor 5A siRNA

Teikoku Hormone accelerates new drug development

VALOR study of Talent thoracic stent graft system

SHP-1 identified as a negative modulator of insulin signaling and hepatic insulin clearance

CXCR3 ligands characterized in vitro using NBI-74330

ALK5 inhibitor effective in nephritis-induced renal fibrosis in rats

Sativex launched in Canada

Talactoferrin shows promise in the treatment of diabetic neuropathic ulcers

Clinical evidence supports the use of decitabine in MDS

Levemir receives FDA approval

Update on the effects and safety of tipifarnib in hematological malignancies

Exenatide reported effective as second-line therapy for type 2 diabetes

Recent patents describe novel antiinfective agents

New treatments claimed for lipoprotein disorders and obesity

New 5-HT receptor agonists for gastrointestinal disorders claimed by Pfizer